Markets

Cancer biotech Syndax Pharmaceuticals sets terms for $60 million IPO

Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for resistant breast cancer, announced terms for its IPO on Thursday. The Waltham, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $179 million. Syndax Pharmaceuticals, which was founded in 2005, plans to list on the NASDAQ under the symbol SNDX. It initially filed confidentially on November 15, 2013. Deutsche Bank and Jefferies are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SNDX

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More